prazosin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 4 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Active influx of imatinib in chronic myeloid leukemia (CML) cells is mediated by the organic cation transporter 1 (OCT-1)." | 1.36 | Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. ( Engler, JR; Frede, A; Hughes, TP; Saunders, VA; White, DL; Zannettino, AC, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eadie, LN | 1 |
| Hughes, TP | 3 |
| White, DL | 3 |
| Engler, JR | 1 |
| Frede, A | 1 |
| Saunders, VA | 1 |
| Zannettino, AC | 1 |
| Eadie, L | 1 |
| Forchap, SL | 1 |
| Pirmohamed, M | 1 |
| Clark, RE | 1 |
4 other studies available for prazosin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Humans; Imatinib Mesylate; Leu | 2018 |
Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.
Topics: Adrenergic alpha-Antagonists; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B; ATP Bin | 2010 |
Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.
Topics: Adrenergic alpha-Antagonists; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leuk | 2010 |
Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis.
Topics: Amantadine; Apoptosis; Calcium; Caspases; Cell Membrane Permeability; Drug Synergism; Humans; K562 C | 2012 |